



CMV Forum 3

**June 18, 2016
Boston, MA**



Facilitating collaborative research in drug
development and health policy

Steering Committee

Michelle Berrey, <i>Co-chair</i>	Chimerix, Inc.
Per Ljungman, <i>Co-chair</i>	Karolinska Institutet
Paul Baum	Roche Molecular Systems
Michael Boeckh	University of Washington
Gavin Cloherty	Abbott Molecular
Lesia Dropulic	NIH/NIAID
Jay Erdman	Astellas Pharma, Inc.
Paul Griffiths	University College London
Atul Humar	University of Toronto
Peter Hunt	University of California, San Francisco
Filip Josephson	EMA
Takashi Komatsu	FDA/CDER
Philip Krause	FDA/CBER
Li Li	FDA/CDRH
Francisco Martinez-Murillo	FDA/CDRH
Veronica Miller	Forum
Jeff Murray	FDA/CDER
Jules O'Rear	FDA/CDER
Randi Leavitt	Merck Research Labs

Berkeley  School of
Public Health



Forum for
Collaborative HIV Research

Financial Sponsors





*Facilitating collaborative research in drug
development and health policy*

Special Thanks

- Ken Mayer
- Fenway Community Health Center



*Facilitating collaborative research in drug
development and health policy*

Forum Staff

- Ben Hauschild
- Megan McIntosh
- Jeff Kaminski



Today's Agenda

- Last discussion round of CMV definitions manuscript
- CMV DNAemia & clinical outcome
 - Review level of current level of evidence
- Discuss collaborative opportunities for biomarker validation
- Lessons learned from phase 3 trials
- Next steps